BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The European School of Multimodality Imaging & Therapy (ESMIT)
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20280326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20281029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20290325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20291028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250301T080000
DTEND;TZID=Europe/Vienna:20270330T170000
DTSTAMP:20260613T041452
CREATED:20251117T100100Z
LAST-MODIFIED:20251117T102105Z
UID:3297-1740816000-1806426000@esmit.eanm.org
SUMMARY:Fundamentals of Research in Imaging and Theranostics Part 2
DESCRIPTION:UEMS EACCME has granted the accreditation of 4.5 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nThis online course is part of a longer line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation\, as well as the design\, conductance and reporting of clinical research trials\, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications. \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\nFor phase I/II clinical studies with radiopharmaceuticals to understand:    \n\n\n\n\nThe principles of technical realisation of the study including assessment of safety of investigational medicinal product \n\n\n\nThe statistical considerations\, including the estimation of number of subjects to be enrolled  \n\n\n\nThe regulatory requirements for performing clinical studies with radiopharmaceutical with special focus on diagnostic radiopharmaceuticals and to summarise the particularities of these studies \n\n\n\nThe ethical and medical considerations in common and vulnerable populations \n\n\n\nThe principles of preparing the clinical study protocol  \n\n\n\nThe objectives\, endpoints and outcome measures  \n\n\n\nThe principles of patient selection\, inclusion and non-inclusion criteria \n\n\n\nThe principles of establishment of the standard of truth\, the role of the comparator\, superiority/non-inferiority/equivalence(?) studies) & practical examples\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\n\nPersonnel involved in designing and/or performing phase I/II clinical research with diagnostic radiopharmaceuticals (e.g. nuclear medicine physicians\, pharmacists\, physicists\, nurses\, technologist\, administrative staff). \n\n\n\nPersonnel involved in assessment of the ethical\, medical and methodologic aspects of phase I/II research protocols with diagnostic radiopharmaceuticals. \n\n\n\nAll professionals interested in phase I/II clinical research with diagnostic radiopharmaceuticals \n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nChiara GranaSpeaker \n\n\n\n\n\nBart de KeizerSpeaker \n\n\n\n\n\nCaroline StokkeSpeaker \n\n\n\n\n\nJean-Noel TalbotSpeaker \n\n\n\n\n\n\n\nLuisa Roldao PereiraSpeaker \n\n\n\n\n\nJohn Andrei IagaruSpeaker \n\n\n\n\n\nSona BalogovaSpeaker
URL:https://esmit.eanm.org/event/fundamentals-of-research-part-2/
CATEGORIES:Online Course,Research Methods,Self-paced Online Course,Theranostics
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251030T080000
DTEND;TZID=Europe/Vienna:20271130T170000
DTSTAMP:20260613T041452
CREATED:20240228T100725Z
LAST-MODIFIED:20251118T083202Z
UID:1520-1761811200-1827594000@esmit.eanm.org
SUMMARY:Bringing Alpha Therapies into Clinical Practice
DESCRIPTION:UEMS EACCME has granted the accreditation of 3 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nThis online course offers a comprehensive introduction to alpha therapy in nuclear medicine\, with a focus on the fundamental principles and clinical applications of Alpha-Therapy in the fields of Radiopharmaceutical Sciences\, Oncology and Dosimetry. Alpha Therapy is a cutting-edge cancer treatment using alpha radiation. It represents a form of targeted radionuclide therapy that uses alpha-emitting radioisotopes to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. It is highly efficient and lately increasingly explored for scientific purposes in the oncologic domain . With this course we aim at bringing Alpha Therapies into clinical practice through various\, relevant presentations. A panel of experts and EANM members will update you on the type of alpha-emitting radioisotopes available\, describing all important steps required for production and radiopharmaceutical development. The advantages\, but also the challenges related to the use of Alpha therapy will amply be discussed and supported by clinical examples. You will be initiated in the existing and ongoing therapeutic trials\, with the best yet to come. Dosimetry will play a pivotal role in this course\, underlying its role in clinical practice. Finally\, The Alphamet project will be presented\, allowing you to get updated with the latest insights from Theranostics. \n\n\n\n \n\n\n\nRPH \n\n\n\nTargeted Alpha Therapy (TAT) represents a cutting-edge advancement in cancer treatment\, harnessing the potent\, cell-killing power of alpha particles to precisely destroy malignant cells while minimizing damage to surrounding healthy tissue. This part of the course course explores the transformative potential of TAT\, highlighting its exceptional potency\, unique ability to overcome radio-resistance\, and its role in modern theranostics. You’ll gain insight into the selection of optimal alpha-emitting radionuclides\, the biological advantages of short-range high-energy emissions\, and the complex challenges involved in the development\, production\, and clinical translation of these innovative therapies. Join us to deepen your knowledge and be part of the future of targeted radiopharmaceuticals in oncology. \n\n\n\nOncology \n\n\n\n \n\n\n\nIn this part of the course\, participants will explore the main advantages of alpha-emitting radionuclides in oncology\, while also gaining an understanding of the clinical challenges associated with their use. You will become familiar with the key clinical aspects of Alpha-Therapy\, supported by real-world perspectives and case insights. The course also highlights current and upcoming therapeutic trials\, providing valuable knowledge on the future direction of this rapidly evolving field. \n\n\n\nDosimetry \n\n\n\nParticipants will begin by exploring the basic concepts of dosimetry with alpha emitters\, highlighting key differences from beta emitter dosimetry. The course then delves into the clinical relevance of alpha dosimetry\, demonstrating how accurate dose assessments can inform and optimize the management of patients undergoing treatment with alpha radiotherapeutics. In addition\, the course presents the Alphamet project\, a major European initiative that addresses the specific metrological challenges associated with targeted alpha therapies. By examining the goals and contributions of Alphamet\, learners will gain insight into how this research supports the safe and effective integration of alpha therapy into routine clinical practice. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo gain an overview of the main advantages of Alpha-radionuclides\n\n\n\nTo learn about the challenges of alpha emitters\, complex production; transport issues\, waste management and handling\n\n\n\nTo get insights on radiobiology: radiotoxicity & effectiveness\n\n\n\nTo have a comprehensive review of research candidates\n\n\n\nTo provide an overview of the main advantages when using Alpha-Therapy in clinical practice\n\n\n\nTo learn about the clinical challenges when using Alpha-Therapy\n\n\n\nTo get insights into current and future trials focusing on Alpha-Therapy\n\n\n\nTo learn the most basic aspects about dosimetry of alpha emitters showing the main differences with dosimetry of beta emitters\n\n\n\nTo learn how dosimetry results could be used in the management of patients treated with radiopharmaceuticals that include alpha emitters\n\n\n\nTo learn on the Alphamet project\, which addresses the unique and unmet metrological challenges of targeted alpha therapies\, contributing to their safe and optimised implementation into routine clinical practice\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear medicine physicians\, radiologists\, medical oncologists\, urologists\, radiation oncologists\, medical physicists\, biologists\, researchers\n\n\n\nRadiochemists\, radiopharmacists\, physicists\, medical physicists\, biologists\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeClick to see the full event programme. View the Programme\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n\n\nDana NiculaeSpeaker \n\n\n\n\n\nEmma AnaheimSpeaker \n\n\n\n\n\nJanke KleyhansSpeaker \n\n\n\n\n\nMarianna TosatoSpeaker \n\n\n\n\n\nWolfgang FendlerSpeaker \n\n\n\n\n\nMathias ZacherlSpeaker \n\n\n\n\n\n\n\nPablo Mínguez GabiñaSpeaker \n\n\n\n\n\nMike SathekgeSpeaker \n\n\n\n\n\nDaniela Oprea-LagerSpeaker \n\n\n\n\n\nAna Denis-BacelarSpeaker \n\n\n\n\n\nJoe O’SullivanSpeaker \n\n\n\n\n\n\n\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\nEnroll yourselfFind your desired course under ‘Online Courses’  \n\n\n\nEnjoy!Once enrolled\, you get full access to the course contents on the ESMIT eLearning platform \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/bringing-alpha-therapies-into-clinical-practice-2/
LOCATION:Online
CATEGORIES:Clinical Nuclear Medicine,Online Course,Radiopharmaceuticals,Self-paced Online Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251103T000000
DTEND;TZID=Europe/Vienna:20271130T235959
DTSTAMP:20260613T041452
CREATED:20251030T092126Z
LAST-MODIFIED:20260309T102411Z
UID:3146-1762128000-1827619199@esmit.eanm.org
SUMMARY:NucMed Essentials - MSK Basics
DESCRIPTION:UEMS EACCME has granted the accreditation of 5 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nNew ESMIT Learning format: Self-paced online course followed by a live session with the course faculty\, where participants are able to ask their questions live!* \n\n\n\n \n\n\n\n \n\n\n\nNuclear Medicine Essentials: The Basics of MSK provides a comprehensive introduction to musculoskeletal applications in nuclear medicine\, focusing on both diagnostic and therapeutic techniques. Participants will explore the fundamental principles of bone scintigraphy\, including its physiological basis\, imaging protocols\, and wide range of clinical applications\, with emphasis on its continued importance in patient care. The course also delves into advanced imaging through NaF PET\, highlighting its uptake mechanisms\, technical considerations\, and growing role in oncology and other clinical contexts. Building on these diagnostic foundations\, the course transitions into therapeutic strategies\, such as the use of Radium-223 in the treatment of bone metastases\, with attention to efficacy\, safety\, and radioprotection measures. \n\n\n\nBeyond theoretical understanding\, the program emphasizes practical application and clinical relevance. Learners will gain exposure to cutting-edge research\, evidence-based workflows\, and therapeutic innovations in the field. Radiosynovectomy for arthritis treatment is presented as an important example of nuclear medicine’s therapeutic scope\, with procedural insights and expected outcomes supported by real-world case demonstrations. Departmental video presentations supplement each topic\, offering participants a unique opportunity to see workflows and protocols in practice. By the end of the course\, attendees will not only understand the fundamentals of musculoskeletal nuclear medicine but also appreciate its evolving role in modern imaging and therapy.  \n\n\n\n \n\n\n\n \n\n\n\n*The live follow-up session will only be held if there is interest – please submit your questions at the dedicated space on our eLearning platform. The date of the live session will be announced in due time. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\nI. Understand the fundamentals of bone scan techniques: \n\n\n\n \n\n\n\n\nDescribe the theoretical considerations and acquisition protocols for bone scans.\n\n\n\nExplain the clinical applications of bone scans across various pathologies.\n\n\n\n\nII. Gain insights into NaF PET for bone imaging: \n\n\n\n\nSummarize the theoretical considerations and acquisition protocols specific to NaF PET.\n\n\n\nRecognize the essential applications of NaF PET in oncology and other clinical cases.\n\n\n\n\nIII. Explore therapeutic approaches for bone metastases using bone-seeking agents: \n\n\n\n\nReview current theoretical knowledge and recent publications on the treatment of bone metastases.\n\n\n\nIdentify practical considerations and procedural steps involved in bone-seeking agent therapies.\n\n\n\n\nIV. Learn the application of radiosynovectomy in managing arthritis: \n\n\n\n\nDescribe the indications\, procedures\, and expected outcomes of radiosynovectomy for arthritis treatment.\n\n\n\n\n \n\n\n\n \n\n\n\nV. Apply knowledge through visual and practical insights from real-world clinical settings: \n\n\n\n\nAssess clinical workflows and procedural nuances via department video presentations for each session.\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nTechnologists\, nuclear medicine physicians and residents \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nKnut LiepeSpeaker \n\n\n\n\n\nJules Zhang-YinSpeaker \n\n\n\n\n\nPaolo TurcoSpeaker
URL:https://esmit.eanm.org/event/nucmed-essentials-msk-basics/
CATEGORIES:NucMed Essentials
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260130T000000
DTEND;TZID=Europe/Vienna:20280130T235959
DTSTAMP:20260613T041452
CREATED:20260113T132906Z
LAST-MODIFIED:20260223T101002Z
UID:3455-1769731200-1832889599@esmit.eanm.org
SUMMARY:Personalized Medicine in Prostate Cancer: From Diagnostic to Therapy
DESCRIPTION:This course has been accredited with 3 CME credits by the UEMS EACCME. \n\n\n\nRadiolabelled prostate-specific membrane antigen (PSMA) is increasingly used in imaging and treatment of prostate cancer. PSMA-directed radionuclide therapy is an efficacious new treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) and beyond. The online course will cover the spectrum of radiolabelled PSMA tracers\, techniques related to PSMA imaging\, from diagnosis to therapy\, with lectures\, interactive case discussions\, and relevant information for clinical practice. \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seat!Enter the eLearning platform  register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\nPSMA PET-CT imaging- science and practice:  \n\n\n\n\nTo provide an overview of clinical applications\, normal biodistribution\, variants\, pitfalls and artefacts in PSMA PET-CT \n\n\n\nTo learn how to report PSMA PET-CT scans in primary staging and recurrence\n\n\n\n\n \n\n\n\nRadionuclide PSMA therapy-science and practice (177Lu-PSMA therapies): \n\n\n\n\nTo gain knowledge on PSMA patients selection\, management of common clinical challenges in implementing and delivering of radionuclide therapies\, side effects and their management\n\n\n\nTo discuss current evidence and trends related to 177Lu-PSMA therapies \n\n\n\nTo learn about new or emerging targets and radioisotopes for Prostate cancer management\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nGeneral nuclear medicine specialists\, residents\, radiologists\, healthcare specialists who want to update their knowledge on molecular imaging and radionuclide therapy of prostate cancer including theranostics. \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nKarolien GoffinSpeaker \n\n\n\n\n\nWolfgang FendlerSpeaker
URL:https://esmit.eanm.org/event/personalized-medicine-in-prostate-cancer-from-diagnostic-to-therapy/
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260227T000000
DTEND;TZID=Europe/Vienna:20270227T235959
DTSTAMP:20260613T041452
CREATED:20260512T122929Z
LAST-MODIFIED:20260512T123532Z
UID:3661-1772150400-1803772799@esmit.eanm.org
SUMMARY:EANM Focus Meeting 7: Molecular Imaging for a Personalised Treatment in Alzheimer's Disease
DESCRIPTION:Alzheimer’s disease is a growing global health concern\, now facing a pivotal moment with the approval of disease-specific treatments. \n\n\n\nThis Focus Meeting brought together international experts under the theme ‘An accurate diagnosis for an effective treatment with Molecular Imaging’ to explore the crucial role of imaging and biomarkers in improving diagnosis\, treatment selection\, and monitoring. \n\n\n\nThe goal was to reach a multidisciplinary consensus on the current state of the art and to make expert recommendations how to advance the field towards establishing clinical impact. \n\n\n\n\n\n\n\n\n\nRegister nowEnrol in the online course now for free! Register now\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\n\nCecilia BoccaliniSpeaker \n\n\n\n\n\nPaul BoonSpeaker \n\n\n\n\n\nAngelaBradshawSpeaker \n\n\n\n\n\nDiegoCecchinSpeaker \n\n\n\n\n\nJavierArbizuSpeaker \n\n\n\n\n\nFedericaAgostaSpeaker \n\n\n\n\n\n\n\n\n\nMatthiasBrendelSpeaker \n\n\n\n\n\nRikOssenkoppeleSpeaker \n\n\n\n\n\nSebastianEngelborghsSpeaker \n\n\n\n\n\nAlexanderDrzezgaSpeaker \n\n\n\n\n\nNicolaiFranzmeierSpeaker \n\n\n\n\n\nGiovanniFrisoniSpeaker \n\n\n\n\n\n\n\n\n\nValentina GaribottoSpeaker \n\n\n\n\n\nTakeshiIwatsuboSpeaker \n\n\n\n\n\nShorenaJanelidzeSpeaker \n\n\n\n\n\nFrankJessenSpeaker \n\n\n\n\n\nRenaudLa JoieSpeaker \n\n\n\n\n\nSilviaMorbelliSpeaker \n\n\n\n\n\n\n\n\n\nVincentPlance Speaker \n\n\n\n\n\nLucaRoccatagliataSpeaker \n\n\n\n\n\nPedroRosa-NetoSpeaker \n\n\n\n\n\nPhilipScheltensSpeaker \n\n\n\n\n\nJoySniderSpeaker \n\n\n\n\n\nCharlotteTeunissenSpeaker \n\n\n\n\n\n\n\n\n\nNellekeTolboom Speaker \n\n\n\n\n\nElsmariekevan de GiessenSpeaker \n\n\n\n\n\nKoen van LaereSpeaker \n\n\n\n\n\nAndrea VarroneSpeaker \n\n\n\n\n\nIgorYakushevSpeaker
URL:https://esmit.eanm.org/event/eanm-focus-meeting-7-molecular-imaging-for-a-personalised-treatment-in-alzheimers-disease/
CATEGORIES:Clinical Nuclear Medicine,Self-paced Online Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260619T133000
DTEND;TZID=Europe/Vienna:20260619T143000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20260602T125748Z
UID:2856-1781875800-1781879400@esmit.eanm.org
SUMMARY:Navigating International Guidelines for the Management of Thyroid Cancer
DESCRIPTION:This interactive webinar provides a comprehensive analysis of current international guidelines for the management of thyroid cancer. Expert faculty will present the evolving landscape of scientific society recommendations\, highlighting key differences in strategies. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n   Upon completion of this webinar\, participants will be able to: \n\n\n\n \n\n\n\n\nCompare and contrast international guidelines (ATA\, ETA\, EANM and other ) regarding management of thyroid nodule\n\n\n\nIdentify appropriate patient selection criteria for RAI treatment based on risk stratification\n\n\n\nEvaluate recommended RAI activities for ablation versus therapy\, interpret post-therapy imaging findings\n\n\n\nImplement evidence-based protocols for patient preparation and radiation safety measures\n\n\n\nDevelop personalized follow-up strategies to monitor treatment efficacy\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear Medicine professionals\, Endocrinologists\, Oncologists\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nHenning WeisSpeaker \n\n\n\n\n\nDesiree DeandreisSpeaker \n\n\n\n\n\nMichael KreisslModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/navigating-international-guidelines-for-the-management-of-thyroid-cancer/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260630T080000
DTEND;TZID=Europe/Vienna:20280630T170000
DTSTAMP:20260613T041452
CREATED:20260519T123644Z
LAST-MODIFIED:20260520T092320Z
UID:3713-1782806400-1845997200@esmit.eanm.org
SUMMARY:NucMed Essentials - Artifical Intelligence Basics
DESCRIPTION:This course is not yet available\, but coming soon! \n\n\n\n \n\n\n\nArtificial Intelligence (AI) is transforming the landscape of nuclear medicine\, enhancing image analysis\, improving diagnostic accuracy\, optimizing treatment planning\, and streamlining patient management. As AI-driven technologies continue to evolve\, nuclear medicine professionals must develop a strong foundational understanding of AI concepts to effectively integrate these advancements into clinical practice. \n\n\n\nThis online course\, “Essentials of AI for Nuclear Medicine\,” provides a structured introduction to AI\, covering key topics such as machine learning (ML)\, deep learning (DL)\, and cutting-edge AI approaches\, including generative AI. Participants will gain insights into how AI algorithms work\, their applications in nuclear medicine imaging and theranostics\, and the practical challenges associated with implementing AI in a clinical setting. \n\n\n\nThe course introduces fundamental AI principles\, including supervised and unsupervised learning\, neural networks\, convolutional neural networks (CNNs)\, transformer-based architectures\, and generative models such as GANs and diffusion models. Special emphasis will be placed on AI’s role in PET and SPECT imaging\, lesion detection\, segmentation\, dosimetry\, and radiopharmaceutical therapy (RPT). \n\n\n\nDesigned for nuclear medicine physicians\, medical physicists\, technologists\, and researchers\, this course bridges the gap between AI and clinical applications\, empowering participants to critically understand AI tools and leverage AI-driven technologies in their daily practice. Through six hours of online lectures\, attendees will gain the knowledge and confidence to navigate the evolving intersection of AI and nuclear medicine effectively. Medicine\,” is designed to provide nuclear medicine professionals with a fundamental understanding of AI concepts\, including machine learning (ML)\, deep learning (DL)\, and emerging AI technologies such as generative AI. The course will bridge the gap between AI and clinical practice\, empowering participants to integrate AI solutions into their workflow. \n\n\n\n \n\n\n\n\n\n\n\nRegistration will be open soonThe link to register will be available shortly. Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\n\nTo understand the fundamental principles of Artificial Intelligence (AI)\n\n\n\nTo learn about key AI architectures\n\n\n\nTo stay informed about the applications of AI in nuclear medicine\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\nNuclear medicine physicians\, medical physicits\, technologies and researchers\, who have no AI experience \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nLászló PappSpeaker \n\n\n\nMathieu HattDesignation \n\n\n\n\n\nDimitris VisvikisDesignation \n\n\n\n\n\nKuangyu ShiDesignation
URL:https://esmit.eanm.org/event/nucmed-essentials-artifical-intelligence-basics/
CATEGORIES:NucMed Essentials
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260703T133000
DTEND;TZID=Europe/Vienna:20260703T143000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20251001T091236Z
UID:2859-1783085400-1783089000@esmit.eanm.org
SUMMARY:Auger Electron Emitters – Why Consider this Therapeutic Option?
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/auger-electron-emitters-why-consider-this-therapeutic-option/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260709T090000
DTEND;TZID=Europe/Vienna:20260710T123000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20260612T073152Z
UID:2829-1783587600-1783686600@esmit.eanm.org
SUMMARY:PET in Multiple Myeloma: Evidences\, Applications and Perspectives
DESCRIPTION:This onsite course on FDG PET/CT in multiple myeloma is a focused\, practice-oriented training programme designed to enhance expertise in metabolic imaging of plasma cell disorders. The course integrates concise lectures\, case discussions\, and supervised workstation-based interpretation to provide immersive\, hands-on learning.The programme includes a review of the pathophysiology of multiple myeloma and the biological mechanisms underlying FDG uptake. Faculty outline current evidence and guideline recommendations for PET/CT in staging\, treatment response assessment\, and leasions detection\, as well as MRI applications. Participants learn optimal patient preparation\, acquisition protocols\, and technical considerations that influence image quality and quantitative analysis\, including harmonization strategies.  A central component of the course is interactive case interpretation across diverse disease settings. Attendees analyze studies from patients with smoldering myeloma\, newly diagnosed active disease\, plasmacytomas. Special attention is given to identifying focal lesions\, diffuse bone marrow infiltration\, extramedullary and paramedullary disease\, and to distinguishing viable tumour from post-treatment changes. Structured reporting workshops guide participants in applying standardized interpretation criteria and incorporating metabolic findings into clinically meaningful reports. Correlation with laboratory markers\, bone marrow biopsy results\, and other imaging modalities reinforces integrated decision-making. \n\n\n\nBy the end of the course\, participants gain practical confidence in accurate interpretation\, standardized reporting\, and clinical application of FDG PET/CT across the full spectrum of multiple myeloma disease scenarios.  \n\n\n\n\n\n\n\nRegisteration is closedIf you are still interested in joining the course\, please contact us under esmit@eanm.org \n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo review current clinical indications and guidelines for FDG PET/CT in plasma cell disorders\, including staging\, response assessment\, minimal residual disease evaluation\, and relapse detection.\n\n\n\n\n\nTo develop practical skills in image interpretation across different disease settings\, including smoldering myeloma\, newly diagnosed active disease\, solitary plasmacytoma\, treated disease\, and relapsed or refractory myeloma.\n\n\n\n\n\nTo recognize and characterize patterns of disease involvement\, such as focal lesions\, diffuse bone marrow infiltration\, extramedullary disease\, and paramedullary extension.\n\n\n\n\n\nTo identify common pitfalls and artifacts in PET/CT imaging and distinguish active disease from post-therapeutic changes\, fractures\, inflammation\, or infection.\n\n\n\n\n\nTo apply standardized interpretation and reporting criteria\, incorporating semi-quantitative parameters (e.g.\, SUV measurements) into structured\, clinically meaningful reports.\n\n\n\n\n\nTo integrate PET/CT findings with clinical\, laboratory\, and histopathological data to support multidisciplinary decision-making.\n\n\n\n\n\nTo enhance confidence in independent reporting and clinical application of FDG PET/CT in the management of patients with multiple myeloma.\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\nNuclear Medicine Physicians \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDavideBezziSpeakerCesena/Forlì\, Italy \n\n\n\n\n\nChristos SachpekidisSpeakerAlexandroupolis\, Greece \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nNEW Department Package: If you send 5 participants from your department\, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you. \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/pet-in-multiple-myeloma-evidences-applications-and-perspectives/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260821T120000
DTEND;TZID=Europe/Vienna:20260821T130000
DTSTAMP:20260613T041452
CREATED:20260519T121442Z
LAST-MODIFIED:20260519T122534Z
UID:3700-1787313600-1787317200@esmit.eanm.org
SUMMARY:JSNM/ESMIT - SPECT and PET in the Contemporary Assessment of Cardiac Amyloidosis
DESCRIPTION:This joint webinar will provide a focused and clinically relevant overview of the role of nuclear medicine in the evaluation of cardiac amyloidosis. The first lecture will address the established value of bone-avid tracer SPECT/CT for non-invasive diagnosis\, including acquisition strategy\, image interpretation\, common pitfalls and integration with the broader diagnostic work-up. The second lecture will explore the evolving contribution of PET\, highlighting tracer biology\, quantitative opportunities\, disease characterization and the potential role of PET for earlier detection and treatment monitoring. Together\, the two talks will offer attendees a practical and up-to-date framework for understanding how SPECT and PET can complement each other along the diagnostic and management pathway of patients with suspected or confirmed cardiac amyloidosis. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nReview the current role of bone-avid tracer SPECT/CT in the non-invasive diagnosis of cardiac amyloidosis\, including key interpretation criteria and diagnostic pitfalls.\n\n\n\nUnderstand the emerging value of PET in cardiac amyloidosis\, with emphasis on tracer selection\, disease characterization\, quantification and future clinical applications.\n\n\n\nIntegrate nuclear medicine findings into a multidisciplinary diagnostic pathway\, improving confidence in image interpretation and supporting patient-centered clinical decision-making.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\nNuclear Medicine physicians\, Cardiologists with a focus on cardiovascular imaging\, Radiologists\, Internists involved in amyloidosis care\, Technologists\, Fellows and Residents. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nTakashi KudoSpeaker \n\n\n\n\n\nPierre-Yves MarieSpeaker \n\n\n\n\n\nFederico CaobelliModerator
URL:https://esmit.eanm.org/event/jsnm-esmit-spect-and-pet-in-the-contemporary-assessment-of-cardiac-amyloidosis/
CATEGORIES:Live Webinars
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260918T133000
DTEND;TZID=Europe/Vienna:20260918T143000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20251001T091347Z
UID:2861-1789738200-1789741800@esmit.eanm.org
SUMMARY:Trustworthy AI and Human Oversight
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/trustworthy-ai-and-human-oversight/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260924T090000
DTEND;TZID=Europe/Vienna:20260925T123000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20251111T123139Z
UID:2831-1790240400-1790339400@esmit.eanm.org
SUMMARY:Prostate Cancer Theranostics
DESCRIPTION:More information will come soon. \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeThe programme will come soon. View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nNEW Department Package: If you send 5 participants from your department\, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you. \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/prostate-cancer-theranostics-2/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261106T133000
DTEND;TZID=Europe/Vienna:20261106T143000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20251001T091508Z
UID:2863-1793971800-1793975400@esmit.eanm.org
SUMMARY:With a Little Help of Artificial Intelligence for the Sake of Radiation Protection
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/with-a-little-help-of-artificial-intelligence-for-the-sake-of-radiation-protection/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261112T090000
DTEND;TZID=Europe/Vienna:20261113T123000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20250930T145535Z
UID:2833-1794474000-1794573000@esmit.eanm.org
SUMMARY:Biomarker Assessment for an Early Biological Diagnosis of Alzheimer's Disease
DESCRIPTION:More information will come soon. \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeThe programme will come soon. View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeCancellation Policy\n\nCourse Fee               FREE \n\n\n\nCourse includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nCourse does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/biomarker-assessment-for-an-early-biological-diagnosis-of-alzheimers-disease/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261127T133000
DTEND;TZID=Europe/Vienna:20261127T143000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20251111T123905Z
UID:2865-1795786200-1795789800@esmit.eanm.org
SUMMARY:Ring Geometry SPECT/CT System
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/ring-geometry-spect-ct-system/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261203T090000
DTEND;TZID=Europe/Vienna:20261204T123000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20251111T123336Z
UID:2835-1796288400-1796387400@esmit.eanm.org
SUMMARY:Focus on Benign Thyroid Disease: From Thyroid Nodule to Hyperthyroidism and Immune Disease
DESCRIPTION:More information will come soon. \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeThe programme will come soon. View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nNEW Department Package: If you send 5 participants from your department\, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you. \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/focus-on-benign-thyroid-disease-from-thyroid-nodule-to-hyperthyroidism-and-immune-disease-2/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261211T133000
DTEND;TZID=Europe/Vienna:20261211T143000
DTSTAMP:20260613T041452
CREATED:20251004T070000Z
LAST-MODIFIED:20251001T091729Z
UID:2867-1796995800-1796999400@esmit.eanm.org
SUMMARY:Tips and Tricks on Imaging with New CZT SPECT Systems
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/tips-and-tricks-on-imaging-with-new-czt-spect-systems/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261231T000000
DTEND;TZID=Europe/Vienna:20261231T235900
DTSTAMP:20260613T041452
CREATED:20220901T101846Z
LAST-MODIFIED:20251016T123526Z
UID:1315-1798675200-1798761540@esmit.eanm.org
SUMMARY:Fundamentals of Research in Imaging and Theranostics – Part 1: Research Design
DESCRIPTION:UEMS EACCME has granted the accreditation of 4 CME credits for this event. \n\n\n\nThis online course is part of a long line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation\, as well as the design\, conductance and reporting of clinical research trials\, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications.  \n\n\n\nThese first two modules will represent part one of the course.  \n\n\n\nModule 1 will focus on the entire path from preclinical development to clinical translation of an imaging compound\, including the preclinical studies needed for the selection of a new candidate for clinical translation\, an overview of EU legislation on radiopharmaceuticals for diagnosis and therapy\, and the assessment of quality data and non-clinical data (pharmacology\, dosimetry and toxicology) for the IMP dossier.  \n\n\n\nModule 2 will be focused on the design of a proper trial. It will cover: the definition of objectives\, aims\, endpoints\, population\, statistical methods and examples of trial design schemes\, as well as dosimetry as far as healthy organs and in case of therapy tumour-absorbed dose. It will have a special focus on phase 0\, phase 1-2 trial\, early clinical phase 0-1-2 and investigator-driven clinical trial. \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n\n\nLearning Objectives:\n\n\n\nLearn about: \n\n\n\n\nPreclinical development and clinical translation of radiopharmaceuticals \n\n\n\nThe legislation on radiopharmaceuticals with a specific focus on the European scenario \n\n\n\nRequirements of IMPD for radiopharmaceuticals for imaging agents and theranostic/therapeutic molecules Interpretation of preclinical data to properly design and plan the clinical trial \n\n\n\nPhase 0\, phase 1 and phase 2 clinical trials with radiopharmaceuticals design \n\n\n\nPhase 0\, phase 1 and phase 2 clinical trials with radiopharmaceuticals conductance \n\n\n\nGMP\, GLP and GCP principles \n\n\n\nImportance of radioprotection and dosimetric estimates in early phase clinical trials\n\n\n\n\n\n\n\n\n\n\n\n\nTarget Audience:\n\n\n\n\nResearchers\, scientists\, nurses\, pharmacologists\, radiopharmacists\, residents and specialists in Nuclear Medicine/Oncology/Radiology who want to understand how clinical trials with radiopharmaceuticals in the early phase are unique and how the corresponding documents and trial design should be appropriately planned.\n\n\n\n\n\n\n\n\n\n\nProgrammeClick to see the full event programme.  View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nPaola Anna ErbaUniversità degli Studi di Milano-Bicocca\, Italy \n\n\n\n\n\nSona BalogovaComenius University\, Bratislava\, Slovakia \n\n\n\n\n\nElisabeth von GuggenbergMedical University Innsbruck\, Austria \n\n\n\n\n\n\n\nMartina SolliniVita-Salute San Raffaele University\, Milan\, Italy \n\n\n\n\n\nLuigi AlojUniversity of Cambridge\, United Kingdom \n\n\n\n\n\nMeltem OcakIstanbul University\, Turkey \n\n\n\n\n\n\n\nPeter LavermanRadboud Universiteit Nijmegen\, The Netherlands \n\n\n\n\n\nJane SosabowskiQueen Mary\, University of London\, United Kingdom \n\n\n\n\n\nPetra KolencUniversity Medical Centre Ljubljana\, Slovenia \n\n\n\n\n\n\n\nClemens DecristoforoMedical University Innsbruck\, Austria \n\n\n\n\n\nPiotr GarnuszekPOLATOM\, Warsaw\, Poland \n\n\n\n\n\nRenata MikolajczakPOLATOM\, Warsaw\, Poland \n\n\n\n\n\n\n\nTheodosia MainaNCSR Demokritos\, Athens\, Greece \n\n\n\n\n\nMark KonijnenbergErasmus MC\, Rotterdam\, The Netherlands \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration Fee\n\nCourse Fee              Free \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fundamentals-of-research-in-imaging-and-theranostics-part-1-research-design/
LOCATION:Online
CATEGORIES:Research Methods,Self-paced Online Course
END:VEVENT
END:VCALENDAR